NO20160131A1 - Farmasøytisk sammensetning omfattende en polymorf form av 3-(4-amino-1-okso-1,3 dihydro-isoindol-2-yl)-piperidin-1,6-dion - Google Patents
Farmasøytisk sammensetning omfattende en polymorf form av 3-(4-amino-1-okso-1,3 dihydro-isoindol-2-yl)-piperidin-1,6-dionInfo
- Publication number
- NO20160131A1 NO20160131A1 NO20160131A NO20160131A NO20160131A1 NO 20160131 A1 NO20160131 A1 NO 20160131A1 NO 20160131 A NO20160131 A NO 20160131A NO 20160131 A NO20160131 A NO 20160131A NO 20160131 A1 NO20160131 A1 NO 20160131A1
- Authority
- NO
- Norway
- Prior art keywords
- dione
- piperidine
- oxo
- amino
- isoindol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D51/00—Closures not otherwise provided for
- B65D51/24—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes
- B65D51/28—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials
- B65D51/2807—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container
- B65D51/2857—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by displacing or removing an element enclosing it
- B65D51/2864—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by displacing or removing an element enclosing it the element being a plug or like element closing a passage between the auxiliary container and the main container
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Mechanical Engineering (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
Abstract
Det beskrives polymorfe former av 3-(4-amino-1-okso-1,3 dihydro-isoindol-2-yl)-piperidin-2,6-dion. Det beskrives videre polymorfe former, fremstillingsmåter for fremstilling av de polymorfe former og anvendelse av disse.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49972303P | 2003-09-04 | 2003-09-04 | |
PCT/US2004/028736 WO2005023192A2 (en) | 2003-09-04 | 2004-09-03 | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20160131A1 true NO20160131A1 (no) | 2016-01-28 |
NO341039B1 NO341039B1 (no) | 2017-08-14 |
Family
ID=34272860
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20061528A NO336898B1 (no) | 2003-09-04 | 2006-04-04 | Polymorfe former av 3-(4-amino-1-okso-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dion og blandinger derav, sammensetninger og farmasøytiske sammensetninger inneholdende de polymorfe former, og anvendelse |
NO20150253A NO337446B1 (no) | 2003-09-04 | 2015-02-23 | Polymorfe former av 3-(4-amino-1-okso-1,3 dihydro-isonidol-2-yl)-piperidin-1,6-dion og blandinger derav, sammensetninger og farmasøytiske sammensetninger inneholdende de polymorfe former, og anvendelse. |
NO20160131A NO341039B1 (no) | 2003-09-04 | 2016-01-28 | Farmasøytisk sammensetning omfattende en polymorf form av 3-(4-amino-1-okso-1,3 dihydro-isoindol-2-yl)-piperidin-1,6-dion |
NO20161012A NO341035B1 (no) | 2003-09-04 | 2016-06-15 | Farmasøytisk sammensetning omfattende polymorfe former av 3-(4-amino-1-okso-1,3-dihydro-isoindol-2-yl)-piperidin-1,6-dion |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20061528A NO336898B1 (no) | 2003-09-04 | 2006-04-04 | Polymorfe former av 3-(4-amino-1-okso-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dion og blandinger derav, sammensetninger og farmasøytiske sammensetninger inneholdende de polymorfe former, og anvendelse |
NO20150253A NO337446B1 (no) | 2003-09-04 | 2015-02-23 | Polymorfe former av 3-(4-amino-1-okso-1,3 dihydro-isonidol-2-yl)-piperidin-1,6-dion og blandinger derav, sammensetninger og farmasøytiske sammensetninger inneholdende de polymorfe former, og anvendelse. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20161012A NO341035B1 (no) | 2003-09-04 | 2016-06-15 | Farmasøytisk sammensetning omfattende polymorfe former av 3-(4-amino-1-okso-1,3-dihydro-isoindol-2-yl)-piperidin-1,6-dion |
Country Status (37)
Country | Link |
---|---|
US (20) | US7465800B2 (no) |
EP (7) | EP1667682B1 (no) |
JP (6) | JP4733037B2 (no) |
KR (3) | KR20080063862A (no) |
CN (7) | CN1871003B (no) |
AP (1) | AP2324A (no) |
AR (2) | AR047994A1 (no) |
AT (1) | ATE531369T1 (no) |
AU (2) | AU2004270211B2 (no) |
BR (1) | BRPI0414084A (no) |
CA (9) | CA2741575C (no) |
CR (2) | CR8291A (no) |
CY (1) | CY1112017T1 (no) |
DK (5) | DK2426118T3 (no) |
EA (1) | EA009922B1 (no) |
EC (1) | ECSP066467A (no) |
ES (5) | ES2718926T3 (no) |
GE (1) | GEP20104958B (no) |
HK (6) | HK1092388A1 (no) |
HR (1) | HRP20110836T1 (no) |
HU (3) | HUE042071T2 (no) |
IL (5) | IL174067A (no) |
IS (1) | IS8340A (no) |
MA (1) | MA28084A1 (no) |
ME (3) | ME01571B (no) |
MX (6) | MX342025B (no) |
NO (4) | NO336898B1 (no) |
NZ (1) | NZ546054A (no) |
OA (1) | OA13250A (no) |
PE (1) | PE20060284A1 (no) |
PL (5) | PL3045176T3 (no) |
PT (5) | PT3042659T (no) |
RS (3) | RS53104B (no) |
SI (2) | SI1667682T1 (no) |
UA (1) | UA83504C2 (no) |
WO (1) | WO2005023192A2 (no) |
ZA (1) | ZA200601858B (no) |
Families Citing this family (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
ATE374609T1 (de) * | 2000-11-30 | 2007-10-15 | Childrens Medical Center | Synthese von 4-aminothalidomid enantiomeren |
USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
UA83504C2 (en) * | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US20050143344A1 (en) * | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
US20050222209A1 (en) * | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
CA2563810A1 (en) * | 2004-04-23 | 2005-11-10 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension |
CA2612612C (en) | 2005-06-30 | 2014-03-11 | Celgene Corporation | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds |
CA2613548A1 (en) * | 2005-06-30 | 2007-01-11 | Anthrogenesis Corporation | Repair of tympanic membrane using placenta derived collagen biofabric |
EP1919500A2 (en) * | 2005-07-13 | 2008-05-14 | Anthrogenesis Corporation | Treatment of leg ulcers using placenta derived collagen biofabric |
US20070021762A1 (en) * | 2005-07-13 | 2007-01-25 | Qing Liu | Ocular plug formed from placenta derived collagen biofabric |
US20070066512A1 (en) * | 2005-09-12 | 2007-03-22 | Dominique Verhelle | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels |
US20080064876A1 (en) * | 2006-05-16 | 2008-03-13 | Muller George W | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
WO2008021391A1 (en) * | 2006-08-15 | 2008-02-21 | Anthrogenesis Corporation | Umbilical cord biomaterial for medical use |
WO2008042441A1 (en) * | 2006-10-03 | 2008-04-10 | Anthrogenesis Corporation | Use of umbilical cord biomaterial for ocular surgery |
US8071135B2 (en) | 2006-10-04 | 2011-12-06 | Anthrogenesis Corporation | Placental tissue compositions |
WO2008057162A2 (en) | 2006-10-06 | 2008-05-15 | Anthrogenesis Corporation | Native (telopeptide) placental collagen compositions |
KR20210022148A (ko) | 2007-09-28 | 2021-03-02 | 안트로제네시스 코포레이션 | 인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법 |
EP2235213A2 (en) * | 2007-12-20 | 2010-10-06 | Celgene Corporation | Use of micro-rna as a biomarker of immunomodulatory drug activity |
MX2010009344A (es) * | 2008-03-11 | 2012-09-28 | Reddys Lab Ltd Dr | Preparacion de lenalidomida. |
US20110060010A1 (en) * | 2008-03-13 | 2011-03-10 | Tianjin Hemay Bio-Tech Co., Ltd | Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof |
EP2364305A1 (en) * | 2008-11-03 | 2011-09-14 | Generics (UK) Limited | A crystalline form of lenalidomide and a process for its preparation |
DE102008057285A1 (de) | 2008-11-14 | 2010-05-20 | Ratiopharm Gmbh | 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidindion in Form einer festen Lösung |
EP2355802A1 (de) * | 2008-11-14 | 2011-08-17 | Ratiopharm GmbH | Intermediate und orale darreichungsformen enthaltend lenalidomid |
DE102008057335A1 (de) | 2008-11-14 | 2010-05-20 | Ratiopharm Gmbh | Amorphes Lenalidomid |
DE102008057284A1 (de) | 2008-11-14 | 2010-05-20 | Ratiopharm Gmbh | Tabletten enthaltend Lenalidomid und Adhäsionsverstärker |
WO2010056384A1 (en) * | 2008-11-17 | 2010-05-20 | Dr. Reddy's Laboratories Ltd. | Lenalidomide solvates and processes |
US8709411B2 (en) | 2008-12-05 | 2014-04-29 | Novo Nordisk A/S | Combination therapy to enhance NK cell mediated cytotoxicity |
AU2010220204B2 (en) | 2009-03-02 | 2015-10-08 | Generics [Uk] Limited | Improved process |
WO2010129636A2 (en) * | 2009-05-08 | 2010-11-11 | Dr. Reddy's Laboratories Ltd. | Lenalidomide polymorph |
ES2728776T3 (es) | 2009-05-19 | 2019-10-28 | Celgene Corp | Formulaciones de 4-amino-2-(2,6-dioxopiperidin-3-il)isoindolin-1,3-diona |
CN101665484B (zh) * | 2009-07-20 | 2012-11-21 | 上海皓元生物医药科技有限公司 | 一种制备来那度胺的方法 |
BR112012003138A2 (pt) | 2009-08-12 | 2016-03-01 | Synthon Bv | sal de adição de ácido de lenalidomida, processos para preparar um sal de adição de ácido de lenalidomida, e para purificar base de lenalidomina, composição farmacêutica, e, uso de sais de adição de ácido e/ou da composição. |
US20120220777A1 (en) * | 2009-09-16 | 2012-08-30 | Ranbaxy Laboratories Limited | Process for the preparation of a crystalline form of lenalidomide |
TWI475014B (zh) | 2009-09-17 | 2015-03-01 | Scinopharm Taiwan Ltd | 固體形態的3-(4-胺基-1-側氧基-1,3-二氫-異吲哚-2-基)-哌啶-2,6-二酮及其製造方法 |
WO2011050962A1 (en) | 2009-10-29 | 2011-05-05 | Ratiopharm Gmbh | Acid addition salts of lenalidomide |
CN101696205B (zh) * | 2009-11-02 | 2011-10-19 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
CN102060842B (zh) * | 2009-11-02 | 2013-05-08 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
CN102127054B (zh) * | 2009-11-02 | 2013-04-03 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
WO2011061611A1 (en) | 2009-11-19 | 2011-05-26 | Ranbaxy Laboratories Limited | Process for the preparation of form b of lenalidomide |
WO2011069608A1 (en) | 2009-12-09 | 2011-06-16 | Ratiopharm Gmbh | S-lenalidomide, polymorphic forms thereof and blend comprising s- und r-lenalidomide |
CN101817813B (zh) * | 2010-01-15 | 2013-04-10 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮晶体ⅳ及其药用组合物 |
EP4289838A3 (en) | 2010-02-11 | 2024-03-13 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
WO2011111053A1 (en) * | 2010-03-08 | 2011-09-15 | Natco Pharma Limited | Anhydrous lenalidomide form-i |
US9193989B2 (en) | 2010-06-18 | 2015-11-24 | Taiho Pharmaceutical Co., Ltd. | PRPK-TPRKB modulators and uses thereof |
WO2012047878A2 (en) | 2010-10-04 | 2012-04-12 | Lazo, Inc. | Interactive advertisement environment |
US20140031325A1 (en) | 2010-12-06 | 2014-01-30 | Celgene Corporation | Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma |
CN102070606A (zh) * | 2011-02-17 | 2011-05-25 | 江苏先声药物研究有限公司 | 一种雷利度胺a晶型新的制备方法 |
CN102643266B (zh) * | 2011-02-17 | 2015-02-18 | 江苏先声药物研究有限公司 | 一种雷利度胺b晶型的制备方法 |
PE20140983A1 (es) | 2011-03-11 | 2014-08-25 | Celgene Corp | Formas solidas de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos |
ES2727667T3 (es) * | 2011-03-23 | 2019-10-17 | Hetero Research Foundation | Polimorfos de lenalidomida |
US9090585B2 (en) | 2011-03-28 | 2015-07-28 | Deuterx, Llc | 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds |
WO2013005229A1 (en) * | 2011-07-05 | 2013-01-10 | Hetero Research Foundation | Process for lenalidomide |
WO2014066243A1 (en) * | 2012-10-22 | 2014-05-01 | Concert Pharmaceuticals, Inc. | Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} |
WO2014110322A2 (en) | 2013-01-11 | 2014-07-17 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
WO2014110558A1 (en) | 2013-01-14 | 2014-07-17 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
AU2014215458A1 (en) | 2013-02-05 | 2015-08-13 | Anthrogenesis Corporation | Natural killer cells from placenta |
WO2014152833A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
CN104072476B (zh) * | 2013-03-27 | 2018-08-21 | 江苏豪森药业集团有限公司 | 泊马度胺晶型及其制备方法和用途 |
WO2014170909A2 (en) * | 2013-04-01 | 2014-10-23 | Hetero Research Foundation | Process for pomalidomide |
US10260885B2 (en) * | 2013-09-03 | 2019-04-16 | Fugro Chance, Inc. | Interactive remote guidance system for seaborne vessels |
UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
EP2875817B1 (en) * | 2013-11-26 | 2020-03-18 | Synhton B.V. | Pharmaceutical formulation comprising amorphous lenalidomide |
WO2015116802A1 (en) | 2014-01-29 | 2015-08-06 | Otsuka Pharmaceutical Co., Ltd. | Device-based risk management of a therapeutic |
WO2015113314A1 (zh) * | 2014-01-30 | 2015-08-06 | 上海创诺制药有限公司 | 3-(4-氨基-1,3-二氢-1-氧代-2h-异吲哚-2-基)-2,6-哌啶二酮新晶型及其制备方法 |
CN104016966A (zh) * | 2014-01-30 | 2014-09-03 | 上海创诺制药有限公司 | 3-(4-氨基-1,3-二氢-1-氧代-2h-异吲哚-2-基)-2,6-哌啶二酮新晶型及其制备方法 |
RU2016145411A (ru) * | 2014-04-22 | 2018-05-23 | Оцука Фармасьютикал Ко., Лтд. | Комбинация брекспипразола и налмефена, и ее применение для лечения синдрома химической зависимости |
CN105085473B (zh) * | 2014-04-24 | 2019-06-18 | 江苏豪森药业集团有限公司 | 来那度胺晶型及其制备方法和医药用途 |
EP3137450A2 (en) * | 2014-04-26 | 2017-03-08 | Shilpa Medicare Limited | Crystalline lenalidomide process |
US10025472B2 (en) * | 2014-06-01 | 2018-07-17 | Apple Inc. | Method and apparatus for displaying data regarding a device's traversal through a region |
WO2016024286A2 (en) | 2014-08-11 | 2016-02-18 | Avra Laboratories Pvt. Ltd. | An improved process for synthesis of lenalidomide |
RS64038B1 (sr) | 2014-08-22 | 2023-04-28 | Celgene Corp | Postupci za lečenje multiplog mijeloma imunomodulatornim jedinjenjima u kombinaciji sa antitelima |
US9794331B1 (en) * | 2014-09-29 | 2017-10-17 | Amazon Technologies, Inc. | Block allocation based on server utilization |
EP3233082B1 (en) | 2014-12-19 | 2018-12-05 | Synthon B.V. | Pharmaceutical composition comprising amorphous lenalidomide |
WO2016097030A1 (en) | 2014-12-19 | 2016-06-23 | Synthon B.V. | Pharmaceutical composition comprising amorphous lenalidomide |
CN104447689B (zh) * | 2014-12-22 | 2016-07-20 | 上海迈柏医药科技有限公司 | 来那度胺的晶型及其制备方法 |
CN104610210B (zh) * | 2015-02-05 | 2017-06-16 | 天津大学 | 一种脱氢醋酸钠无水物制备方法 |
US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
LT3135275T (lt) | 2015-08-27 | 2020-09-25 | Grindeks, A Joint Stock Company | Farmacinė kompozicija, gebanti įtraukti įvairių kristalinių modifikacijų lenalidomidą |
WO2017109041A1 (en) | 2015-12-22 | 2017-06-29 | Synthon B.V. | Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant |
RU2616976C1 (ru) * | 2016-04-07 | 2017-04-19 | Олег Ростиславович Михайлов | Кристаллическая β-модификация 3-(4-амино-1-оксо-1,3-дигидро-2Н-изоиндол-2-ил)-пиперидин-2,6-диона, способ её получения и фармацевтическая композиция на её основе |
WO2018013693A1 (en) | 2016-07-13 | 2018-01-18 | Celgene Corporation | Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof |
TWI664172B (zh) * | 2016-08-25 | 2019-07-01 | 大陸商浙江海正藥業股份有限公司 | 來那度胺的晶型及其製備方法和用途 |
US11584733B2 (en) | 2017-01-09 | 2023-02-21 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
US11034667B2 (en) | 2017-01-09 | 2021-06-15 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
CN108658935A (zh) * | 2017-03-27 | 2018-10-16 | 天津大学 | 来那度胺新晶型、其制备方法及其医药用途 |
US10093647B1 (en) | 2017-05-26 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof |
CN112062751A (zh) * | 2017-08-04 | 2020-12-11 | 正大天晴药业集团股份有限公司 | 一种来那度胺的新结晶及其药物组合物 |
CN111107874A (zh) | 2017-09-14 | 2020-05-05 | 葛兰素史密斯克莱知识产权发展有限公司 | 用于癌症的组合治疗 |
US10093649B1 (en) | 2017-09-22 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof |
US10093648B1 (en) | 2017-09-22 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof |
US20200246393A1 (en) | 2017-09-28 | 2020-08-06 | Celularity, Inc. | Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody |
KR20200078498A (ko) | 2017-10-26 | 2020-07-01 | 신바이어스 파마 아게 | 레날리도마이드 즉시 방출 제형 |
EP3505158A1 (en) | 2017-12-27 | 2019-07-03 | KRKA, d.d., Novo mesto | Pharmaceutical composition of lenalidomide pharmaceutically acceptable acid addition salt |
CN108191826A (zh) * | 2018-01-08 | 2018-06-22 | 浙江省医学科学院 | 一种来那度胺晶体及其制备方法 |
CA3087565A1 (en) | 2018-01-09 | 2019-07-18 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
US11452722B2 (en) | 2018-01-11 | 2022-09-27 | Natco Pharma Limited | Stable pharmaceutical compositions comprising lenalidomide |
CN108840908A (zh) * | 2018-07-10 | 2018-11-20 | 刘凤娟 | 特拉匹韦的一种新晶型及其制备方法 |
CN111217792B (zh) * | 2018-11-23 | 2021-09-28 | 欣凯医药化工中间体(上海)有限公司 | 一种来那度胺b晶型的制备方法 |
US20220218687A1 (en) | 2021-01-08 | 2022-07-14 | Starton Therapeutics, Inc. | Stable Solutions of Immunomodulatory Imide Compounds for Parenteral Use |
WO2023126531A1 (en) | 2021-12-31 | 2023-07-06 | A Fine House S.A. | Lenalidomide oral solution |
WO2023126530A1 (en) | 2021-12-31 | 2023-07-06 | A Fine House S.A. | Oral solution comprising lenalidomide |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするdna |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
WO1992014455A1 (en) | 1991-02-14 | 1992-09-03 | The Rockefeller University | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US20010056114A1 (en) | 2000-11-01 | 2001-12-27 | D'amato Robert | Methods for the inhibition of angiogenesis with 3-amino thalidomide |
US6114355A (en) | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US6228879B1 (en) | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
BR9509590A (pt) * | 1994-11-04 | 1997-12-23 | Polymun Scient Immunbio Forsch | Aplicação de sod em liposomas |
US5731325A (en) | 1995-06-06 | 1998-03-24 | Andrulis Pharmaceuticals Corp. | Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents |
DE19601303A1 (de) | 1996-01-16 | 1997-07-17 | Boehringer Ingelheim Kg | Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln |
JPH1053576A (ja) * | 1996-06-07 | 1998-02-24 | Eisai Co Ltd | 塩酸ドネペジルの多形結晶およびその製造法 |
AU1153097A (en) | 1996-06-07 | 1998-01-05 | Eisai Co. Ltd. | Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production |
DE69717831T3 (de) * | 1996-07-24 | 2018-08-30 | Celgene Corp. | Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels |
US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
DE69720735T9 (de) | 1996-08-12 | 2005-08-25 | Celgene Corp. | Immunotherapeutische mittel und ihre anwendung in der reduzierung der cytokininwerte |
ATE305301T1 (de) | 1996-11-05 | 2005-10-15 | Childrens Medical Center | Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid |
AU5875598A (en) | 1997-02-05 | 1998-08-26 | University Of Hertfordshire | Preparation of spheroids and their use in medicin or diagnosis |
US5874448A (en) | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
US5955476A (en) | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
CN100390163C (zh) | 1998-03-16 | 2008-05-28 | 赛尔金有限公司 | 2-(2,6-二氧哌啶-3-基)-异二氢吲哚衍生物、其制法及其作为炎性细胞因子抑制剂的用途 |
US6673828B1 (en) | 1998-05-11 | 2004-01-06 | Children's Medical Center Corporation | Analogs of 2-Phthalimidinoglutaric acid |
US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
US20030013739A1 (en) | 1998-12-23 | 2003-01-16 | Pharmacia Corporation | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia |
ES2250121T3 (es) | 1999-03-18 | 2006-04-16 | Celgene Corporation | 1-oxo- y 1,3-dioxoisoindolinas y su empleo en composiciones farmaceuticas para la reduccion de niveles de las citocinas inflamatorias. |
US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
US6326388B1 (en) | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
CZ20022332A3 (cs) * | 2000-01-07 | 2003-01-15 | Transform Pharmaceuticals, Inc. | Sestava vzorků |
CA2319872C (en) | 2000-02-02 | 2012-06-19 | Chun-Ying Huang | Pharmaceutical composition for the treatment of hepatocellular carcinoma |
TR200202194T2 (tr) | 2000-03-17 | 2003-01-21 | Cell Therapeutics, Inc. | Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri |
MXPA02009665A (es) | 2000-03-31 | 2005-09-08 | Celgene Corp | Inhibicion de actividad de ciclooxigenasa-2. |
JP5409981B2 (ja) | 2000-05-15 | 2014-02-05 | セルジーン コーポレイション | 癌治療用の組成物および方法 |
IL155036A0 (en) * | 2000-09-26 | 2003-10-31 | Reddy Research Foundation | Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] benzyl] thiazolidine-2,4-dione maleate and pharmaceutical compositions containing the same |
US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
ATE374609T1 (de) | 2000-11-30 | 2007-10-15 | Childrens Medical Center | Synthese von 4-aminothalidomid enantiomeren |
US20020128228A1 (en) | 2000-12-01 | 2002-09-12 | Wen-Jen Hwu | Compositions and methods for the treatment of cancer |
US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
WO2002068414A2 (en) | 2001-02-27 | 2002-09-06 | The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
JP4494013B2 (ja) | 2001-08-06 | 2010-06-30 | ザ チルドレンズ メディカル センター コーポレイション | 窒素置換サリドマイド誘導体の合成及び抗腫瘍活性 |
US6472563B1 (en) | 2001-11-09 | 2002-10-29 | Sepracor Inc. | Formoterol tartrate process and polymorph |
JP2005536189A (ja) | 2002-04-12 | 2005-12-02 | セルジーン・コーポレーション | 血管新生のモジュレーターの同定方法、それにより見出された化合物および該化合物を使用する治療方法 |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
CN1697655B (zh) | 2002-05-17 | 2013-09-18 | 细胞基因公司 | 使用免疫调节性化合物用于治疗和控制癌症和其它疾病的方法及组合物 |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
CL2004001004A1 (es) | 2003-05-19 | 2005-03-18 | Upjohn Co | Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple. |
UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
EP1675857B1 (en) | 2003-10-22 | 2011-07-13 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto |
ZA200702382B (en) | 2004-09-03 | 2008-08-27 | Celgene Corp | Processes for the preparation of substituted 2-(2,6-dioxoplperidin-3-yl)-1-oxoisoindolines |
US20080064876A1 (en) | 2006-05-16 | 2008-03-13 | Muller George W | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
US20090092343A1 (en) * | 2007-10-05 | 2009-04-09 | Mary Thomson | Locking Bag with Locking Handle |
MX2010009344A (es) * | 2008-03-11 | 2012-09-28 | Reddys Lab Ltd Dr | Preparacion de lenalidomida. |
WO2009111948A1 (zh) | 2008-03-13 | 2009-09-17 | 天津和美生物技术有限公司 | 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用 |
WO2010019435A2 (en) | 2008-08-14 | 2010-02-18 | Teva Pharmaceutical Industries Ltd. | Solid states of atorvastatin potassium |
EP2364305A1 (en) | 2008-11-03 | 2011-09-14 | Generics (UK) Limited | A crystalline form of lenalidomide and a process for its preparation |
EP2355802A1 (de) | 2008-11-14 | 2011-08-17 | Ratiopharm GmbH | Intermediate und orale darreichungsformen enthaltend lenalidomid |
WO2010056384A1 (en) | 2008-11-17 | 2010-05-20 | Dr. Reddy's Laboratories Ltd. | Lenalidomide solvates and processes |
AU2010220204B2 (en) | 2009-03-02 | 2015-10-08 | Generics [Uk] Limited | Improved process |
WO2010129636A2 (en) | 2009-05-08 | 2010-11-11 | Dr. Reddy's Laboratories Ltd. | Lenalidomide polymorph |
CN101580501B (zh) | 2009-06-01 | 2011-03-09 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体 |
BR112012003138A2 (pt) | 2009-08-12 | 2016-03-01 | Synthon Bv | sal de adição de ácido de lenalidomida, processos para preparar um sal de adição de ácido de lenalidomida, e para purificar base de lenalidomina, composição farmacêutica, e, uso de sais de adição de ácido e/ou da composição. |
US20120184746A1 (en) | 2009-09-03 | 2012-07-19 | Ranbaxy Laboratories Limited | Process for the preparation of lenalidomide |
US20120220777A1 (en) | 2009-09-16 | 2012-08-30 | Ranbaxy Laboratories Limited | Process for the preparation of a crystalline form of lenalidomide |
TWI475014B (zh) | 2009-09-17 | 2015-03-01 | Scinopharm Taiwan Ltd | 固體形態的3-(4-胺基-1-側氧基-1,3-二氫-異吲哚-2-基)-哌啶-2,6-二酮及其製造方法 |
WO2011050962A1 (en) | 2009-10-29 | 2011-05-05 | Ratiopharm Gmbh | Acid addition salts of lenalidomide |
CN101696205B (zh) | 2009-11-02 | 2011-10-19 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
WO2011061611A1 (en) | 2009-11-19 | 2011-05-26 | Ranbaxy Laboratories Limited | Process for the preparation of form b of lenalidomide |
WO2011064574A1 (en) | 2009-11-24 | 2011-06-03 | Generics [Uk] Limited | Hplc method for detecting lenalidomide |
WO2011069608A1 (en) | 2009-12-09 | 2011-06-16 | Ratiopharm Gmbh | S-lenalidomide, polymorphic forms thereof and blend comprising s- und r-lenalidomide |
CN101817813B (zh) | 2010-01-15 | 2013-04-10 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮晶体ⅳ及其药用组合物 |
WO2011111053A1 (en) | 2010-03-08 | 2011-09-15 | Natco Pharma Limited | Anhydrous lenalidomide form-i |
CN101791288B (zh) | 2010-04-07 | 2011-12-28 | 南京卡文迪许生物工程技术有限公司 | 一种稳定的来那度胺口服固体制剂 |
CN102453021A (zh) * | 2010-10-22 | 2012-05-16 | 重庆医药工业研究院有限责任公司 | 来那度胺的新晶型及其制备方法 |
-
2004
- 2004-03-09 UA UAA200603659A patent/UA83504C2/uk unknown
- 2004-09-03 AP AP2006003558A patent/AP2324A/xx active
- 2004-09-03 OA OA1200600078A patent/OA13250A/en unknown
- 2004-09-03 PT PT15199521T patent/PT3042659T/pt unknown
- 2004-09-03 CA CA2741575A patent/CA2741575C/en active Active
- 2004-09-03 DK DK11185767T patent/DK2426118T3/da active
- 2004-09-03 US US10/934,863 patent/US7465800B2/en active Active
- 2004-09-03 KR KR1020087012598A patent/KR20080063862A/ko not_active Application Discontinuation
- 2004-09-03 MX MX2013002127A patent/MX342025B/es unknown
- 2004-09-03 CA CA 2687924 patent/CA2687924C/en active Active
- 2004-09-03 EP EP04783095A patent/EP1667682B1/en not_active Revoked
- 2004-09-03 PL PL15199540T patent/PL3045176T3/pl unknown
- 2004-09-03 CA CA2537092A patent/CA2537092C/en active Active
- 2004-09-03 ME MEP-2012-97A patent/ME01571B/me unknown
- 2004-09-03 CN CN200480030852XA patent/CN1871003B/zh not_active Expired - Fee Related
- 2004-09-03 CN CN2011100226894A patent/CN102060843B/zh not_active Expired - Fee Related
- 2004-09-03 WO PCT/US2004/028736 patent/WO2005023192A2/en active Application Filing
- 2004-09-03 CA CA 2688695 patent/CA2688695C/en active Active
- 2004-09-03 CN CN201410197941.9A patent/CN104059052A/zh active Pending
- 2004-09-03 MX MX2012014442A patent/MX346372B/es unknown
- 2004-09-03 CN CN201210126780.5A patent/CN102675281B/zh not_active Expired - Fee Related
- 2004-09-03 EP EP18184669.2A patent/EP3459544A1/en not_active Withdrawn
- 2004-09-03 EP EP15199540.4A patent/EP3045176B8/en not_active Revoked
- 2004-09-03 AU AU2004270211A patent/AU2004270211B2/en active Active
- 2004-09-03 ES ES15199526T patent/ES2718926T3/es active Active
- 2004-09-03 CA CA 2688709 patent/CA2688709C/en active Active
- 2004-09-03 CN CN2010101862479A patent/CN101838261B/zh not_active Expired - Fee Related
- 2004-09-03 CA CA 2688708 patent/CA2688708C/en active Active
- 2004-09-03 RS RS20120340A patent/RS53104B/en unknown
- 2004-09-03 DK DK15199526.3T patent/DK3045175T3/en active
- 2004-09-03 NZ NZ546054A patent/NZ546054A/en not_active IP Right Cessation
- 2004-09-03 RS RS20120339A patent/RS20120339A1/en unknown
- 2004-09-03 MX MX2012014277A patent/MX346261B/es unknown
- 2004-09-03 HU HUE15199521A patent/HUE042071T2/hu unknown
- 2004-09-03 ES ES15199540T patent/ES2718927T3/es active Active
- 2004-09-03 DK DK04783095.5T patent/DK1667682T3/da active
- 2004-09-03 PL PL11185767T patent/PL2426118T3/pl unknown
- 2004-09-03 KR KR1020097015932A patent/KR101005991B1/ko active IP Right Review Request
- 2004-09-03 SI SI200431775T patent/SI1667682T1/sl unknown
- 2004-09-03 EP EP15199521.4A patent/EP3042659B8/en not_active Revoked
- 2004-09-03 DK DK15199540.4T patent/DK3045176T3/en active
- 2004-09-03 MX MXPA06001994A patent/MXPA06001994A/es active IP Right Grant
- 2004-09-03 PT PT15199540T patent/PT3045176T/pt unknown
- 2004-09-03 CA CA 2688694 patent/CA2688694C/en active Active
- 2004-09-03 PT PT15199526T patent/PT3045175T/pt unknown
- 2004-09-03 CA CA 2741412 patent/CA2741412C/en active Active
- 2004-09-03 CA CA 2687927 patent/CA2687927C/en active Active
- 2004-09-03 ES ES04783095T patent/ES2376879T3/es active Active
- 2004-09-03 JP JP2006525471A patent/JP4733037B2/ja active Active
- 2004-09-03 DK DK15199521.4T patent/DK3042659T3/en active
- 2004-09-03 MX MX2012014272A patent/MX346260B/es unknown
- 2004-09-03 EA EA200600535A patent/EA009922B1/ru not_active IP Right Cessation
- 2004-09-03 SI SI200432022T patent/SI2426118T1/sl unknown
- 2004-09-03 CN CN2010101862271A patent/CN101863878B/zh not_active Expired - Fee Related
- 2004-09-03 ES ES11185767T patent/ES2402808T3/es active Active
- 2004-09-03 PL PL04783095T patent/PL1667682T3/pl unknown
- 2004-09-03 CN CN2012100174979A patent/CN102584788A/zh active Pending
- 2004-09-03 ME MEP-2012-98A patent/ME01572B/me unknown
- 2004-09-03 ES ES15199521T patent/ES2718925T3/es active Active
- 2004-09-03 HU HUE15199540A patent/HUE041282T2/hu unknown
- 2004-09-03 GE GEAP20049329A patent/GEP20104958B/en unknown
- 2004-09-03 KR KR20067004521A patent/KR100979869B1/ko active IP Right Review Request
- 2004-09-03 PT PT111857678T patent/PT2426118E/pt unknown
- 2004-09-03 ZA ZA200601858A patent/ZA200601858B/en unknown
- 2004-09-03 BR BRPI0414084-2A patent/BRPI0414084A/pt not_active Application Discontinuation
- 2004-09-03 AT AT04783095T patent/ATE531369T1/de active
- 2004-09-03 ME MEP-2008-776A patent/ME01530B/me unknown
- 2004-09-03 PL PL15199521T patent/PL3042659T3/pl unknown
- 2004-09-03 HU HUE15199526A patent/HUE041265T2/hu unknown
- 2004-09-03 PL PL15199526T patent/PL3045175T3/pl unknown
- 2004-09-03 EP EP20110185757 patent/EP2425836A1/en not_active Withdrawn
- 2004-09-03 PT PT04783095T patent/PT1667682E/pt unknown
- 2004-09-03 RS YUP20060158 patent/RS20060158A/sr unknown
- 2004-09-03 EP EP15199526.3A patent/EP3045175B8/en not_active Revoked
- 2004-09-03 EP EP20110185767 patent/EP2426118B1/en active Active
-
2005
- 2005-03-04 PE PE2005000248A patent/PE20060284A1/es not_active Application Discontinuation
- 2005-03-04 AR ARP050100841A patent/AR047994A1/es not_active Application Discontinuation
-
2006
- 2006-02-21 MX MX2013006320A patent/MX342071B/es unknown
- 2006-03-02 IL IL174067A patent/IL174067A/en not_active IP Right Cessation
- 2006-03-07 IS IS8340A patent/IS8340A/is unknown
- 2006-03-15 CR CR8291A patent/CR8291A/es not_active Application Discontinuation
- 2006-03-30 EC ECSP066467 patent/ECSP066467A/es unknown
- 2006-04-03 MA MA28911A patent/MA28084A1/fr unknown
- 2006-04-04 NO NO20061528A patent/NO336898B1/no unknown
- 2006-12-22 HK HK06114094.0A patent/HK1092388A1/xx not_active IP Right Cessation
-
2008
- 2008-07-23 US US12/220,336 patent/US7977357B2/en active Active
- 2008-12-15 US US12/335,350 patent/US8143286B2/en active Active
- 2008-12-15 US US12/335,262 patent/US8058443B2/en active Active
- 2008-12-15 US US12/335,395 patent/US7855217B2/en active Active
-
2009
- 2009-01-14 US US12/353,383 patent/US9365538B2/en active Active
- 2009-01-23 AU AU2009200257A patent/AU2009200257B2/en not_active Ceased
- 2009-08-05 CR CR10967A patent/CR10967A/es unknown
-
2010
- 2010-08-08 IL IL207458A patent/IL207458A/en not_active IP Right Cessation
- 2010-09-09 JP JP2010201589A patent/JP5309104B2/ja active Active
- 2010-09-27 US US12/891,632 patent/US20110015228A1/en not_active Abandoned
-
2011
- 2011-02-22 JP JP2011035699A patent/JP5925418B2/ja active Active
- 2011-03-08 HK HK11102298A patent/HK1148274A1/xx not_active IP Right Cessation
- 2011-03-30 HK HK11103233A patent/HK1148974A1/xx not_active IP Right Cessation
- 2011-05-26 US US13/117,066 patent/US8431598B2/en active Active
- 2011-09-22 US US13/240,686 patent/US8822499B2/en active Active
- 2011-09-22 US US13/241,022 patent/US9353080B2/en active Active
- 2011-09-22 US US13/240,976 patent/US9371309B2/en active Active
- 2011-10-03 US US13/252,041 patent/US8193219B2/en active Active
- 2011-11-11 HK HK11112211A patent/HK1157772A1/xx not_active IP Right Cessation
- 2011-11-11 CY CY20111101088T patent/CY1112017T1/el unknown
- 2011-11-14 HR HR20110836T patent/HRP20110836T1/hr unknown
-
2012
- 2012-08-27 HK HK12108343A patent/HK1167646A1/xx not_active IP Right Cessation
-
2013
- 2013-04-17 IL IL225791A patent/IL225791A0/en not_active IP Right Cessation
- 2013-04-17 IL IL225792A patent/IL225792A0/en not_active IP Right Cessation
- 2013-05-24 JP JP2013109742A patent/JP2013209407A/ja active Pending
-
2014
- 2014-01-17 JP JP2014006603A patent/JP2014094957A/ja active Pending
-
2015
- 2015-02-23 NO NO20150253A patent/NO337446B1/no unknown
- 2015-03-23 HK HK15102919.7A patent/HK1202531A1/xx unknown
- 2015-05-19 IL IL238911A patent/IL238911A0/en unknown
- 2015-08-14 US US14/827,210 patent/US20160009684A1/en not_active Abandoned
- 2015-11-23 AR ARP150103821A patent/AR102756A2/es unknown
-
2016
- 2016-01-28 JP JP2016014010A patent/JP6200977B2/ja active Active
- 2016-01-28 NO NO20160131A patent/NO341039B1/no unknown
- 2016-06-15 NO NO20161012A patent/NO341035B1/no unknown
- 2016-10-20 US US15/299,243 patent/US20170121305A1/en not_active Abandoned
- 2016-10-20 US US15/299,203 patent/US20170121304A1/en not_active Abandoned
- 2016-10-20 US US15/299,164 patent/US20170121303A1/en not_active Abandoned
-
2017
- 2017-11-03 US US15/803,622 patent/US20180072700A1/en not_active Abandoned
-
2018
- 2018-11-26 US US16/200,514 patent/US10590104B2/en active Active
-
2020
- 2020-03-02 US US16/807,020 patent/US11136306B2/en active Active
-
2021
- 2021-09-02 US US17/465,668 patent/US11655232B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20160131A1 (no) | Farmasøytisk sammensetning omfattende en polymorf form av 3-(4-amino-1-okso-1,3 dihydro-isoindol-2-yl)-piperidin-1,6-dion | |
CY1113926T1 (el) | Μεθοδος κατασκευης πολυμορφικων μορφων 3-(4-αμινο-1-οξο-1,3-διϋδρο-ισοϊνδολ-2-υλ)-πιπεριδινο-2,6-διονης | |
AU2013203194B9 (en) | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |